Generic filters
Filter by content type
Taxonomy terms

APM – Aptorum Group Ltd


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 15

Low: 15

High: 15

Total Analysts: 1

Company Profile

Aptorum Group Limited is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company’s segments include Therapeutics and Non-Therapeutics. Therapeutics segment is seeking to develop various drug molecules (including projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment of human disease conditions to tackle unmet needs, in particular, two of its lead projects targeting infectious disease and cancer (including orphan oncology indications). Non-Therapeutics segment encompasses three businesses, such as diagnostics projects, including a molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology, natural supplements, including NativusWell, and AML Clinic.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan